{
    "2019-10-08": [
        [
            {
                "time": "2018-01-02",
                "original_text": "UPDATE 2-Humira, Rituxan top list of U.S. drugs with biggest price increases -report",
                "features": {
                    "keywords": [
                        "Humira",
                        "Rituxan",
                        "price increases",
                        "U.S."
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Can We See Significant Institutional Ownership On The Eli Lilly and Company (NYSE:LLY) Share Register?",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "institutional ownership",
                        "share register"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "REFILE-UPDATE 1-Humira, Rituxan top list of U.S. drugs with biggest price increases -report",
                "features": {
                    "keywords": [
                        "Humira",
                        "Rituxan",
                        "price increases",
                        "U.S."
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "REFILE-Humira, Rituxan top list of U.S. costliest drug price increases -report",
                "features": {
                    "keywords": [
                        "Humira",
                        "Rituxan",
                        "costliest",
                        "price increases",
                        "U.S."
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Lilly to Unveil New Data for the Treatments of Complex Dermatological Conditions at the 28th Annual European Academy of Dermatology and Venereology (EADV) Congress",
                "features": {
                    "keywords": [
                        "Lilly",
                        "new data",
                        "dermatological conditions",
                        "EADV Congress"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}